There is no single semaglutide dosage chart that fits every product. The brand, route, indication, and presentation must come first. Ozempic injection, Wegovy injection, Wegovy tablets, Ozempic tablets, and Rybelsus use different schedules. Compounded preparations add a separate concentration and measurement question.
This guide summarizes current U.S. adult label schedules and links to the detailed product guides. It is a way to understand a prescription, not to select a dose, convert tablets to injections, or calculate a compounded syringe amount. Ask the prescriber or pharmacist to resolve any mismatch between the chart and your actual package.
Identify four details before reading a dose
Write down the full product name, whether it is swallowed or injected, the reason it is prescribed, and the exact presentation. A pen, prefilled syringe, tablet bottle, and compounded vial can all contain semaglutide while requiring different instructions.
Also distinguish the amount in a complete container from the amount in one prescribed dose. A pen may hold several doses. A concentration describes how much medicine is in a volume; it is not itself the number of milligrams the patient should receive.
Our semaglutide questions guide explains the ingredient and product distinctions. If the label is unclear, obtain written instructions for the actual preparation before using it.
Starting schedules for approved adult products
| Product and route | Labeled starting schedule | What happens afterward |
|---|---|---|
| Ozempic injection | 0.25 mg once weekly for four weeks, then 0.5 mg weekly | Later increases depend on the indication and clinical need; see the separate Ozempic section |
| Wegovy injection | Four-week stages of 0.25, 0.5, 1, and 1.7 mg once weekly | Maintenance depends on the indication, response, and tolerability |
| Wegovy tablets | Thirty-day stages of 1.5, 4, and 9 mg once daily | 25 mg daily from day 91 as the labeled maintenance regimen, if tolerated |
| Ozempic tablets | 1.5 mg daily for days 1–30, then 4 mg daily for days 31–60 | From day 61, maintain 4 mg or increase to 9 mg if additional glycemic control is needed |
| Rybelsus tablets | 3 mg daily for days 1–30, then 7 mg daily for days 31–60 | From day 61, maintain 7 mg or increase to 14 mg if additional glycemic control is needed |
Sources: Ozempic injection label, Wegovy label, and Rybelsus/Ozempic tablet label. These are separate regimens. Rows are not dose equivalents, and changes require the prescribed plan.
Ozempic injection: maintenance depends on the goal
For glycemic control in adults with type 2 diabetes, the Ozempic injection label lists maintenance doses of 0.5, 1, or 2 mg weekly. If more glycemic control is needed, an increase to 1 mg follows at least four weeks at 0.5 mg; an increase to 2 mg follows at least four weeks at 1 mg. The maximum labeled injection dose is 2 mg weekly.
The label has a specific regimen for its kidney-related indication in adults with type 2 diabetes and chronic kidney disease: increase to 1 mg weekly after at least four weeks at 0.5 mg. That is an example of why the treatment purpose matters, not just the ingredient.
The Ozempic dosage guide gives more detail. A larger number is not automatically more appropriate, and a weight-management schedule for another product should not replace this label.
Wegovy injection: the highest dose is not for every indication
For adult weight management, the current Wegovy label lists 1.7 or 2.4 mg weekly as maintenance, with 2.4 mg recommended. For patients who tolerate 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated, the dose may be increased to 7.2 mg weekly.
That 7.2 mg option is not a universal next step, a starting dose, or the maintenance recommendation for every Wegovy indication. Cardiovascular risk reduction and MASH treatment have their own labeled maintenance instructions. Pediatric dosing also differs from the adult high-dose option.
During injection escalation, the label allows the clinician to consider delaying an increase when a dose is not tolerated. See the Wegovy dosage chart for the full indication-specific explanation rather than treating this directory as an individualized schedule.
Daily tablets are not weekly injections in another form
Oral semaglutide uses different formulation and absorption features from injected semaglutide. A larger milligram amount on a tablet does not establish a proportionally stronger effect than a smaller injected amount. Do not divide a weekly injection amount by seven or multiply a daily tablet amount to invent a conversion.
The oral-product label explicitly says that Rybelsus and Ozempic tablets are not substitutable milligram for milligram. Wegovy tablets also have their own approved uses and 25 mg maintenance regimen. The first few strengths can look familiar across brands without making the products interchangeable.
Our oral semaglutide versus injections guide explains the practical differences. Any switch needs a prescriber-selected product, dose, timing, and follow-up plan.
How are the approved tablets taken?
The Wegovy and Rybelsus/Ozempic tablet labels instruct taking one tablet in the morning on an empty stomach with water, up to four ounces. Wait at least 30 minutes before food, other beverages, or other oral medicines. Swallow the tablet whole; do not split, crush, chew, or dissolve it.
These instructions are part of the product’s administration, not optional lifestyle advice. If they conflict with another important medicine’s routine, ask the pharmacist to help arrange the schedule. Do not change food or water timing as an experiment to reduce side effects or increase absorption.
A compounded dissolving tablet, liquid, or other preparation should not be assumed to have the same instructions or evidence as an approved swallowed tablet.
Why start below the eventual maintenance dose?
The labels use gradual escalation to reduce gastrointestinal adverse reactions. A starting period is not a test of whether a person can tolerate the largest available dose. Lack of a dramatic early appetite change does not justify skipping stages.
Contact the prescriber when nausea, vomiting, diarrhea, constipation, or other symptoms interfere with meals, fluids, or daily life. Dose decisions should take benefit and tolerability into account. Our semaglutide nausea guide explains useful observations and symptoms that require assessment.
Do not add another GLP-1 medicine, take extra doses, or borrow leftover medication to accelerate the schedule. A treatment plan becomes harder to evaluate when the actual regimen differs from the prescription.
For a focused explanation, our guide to semaglutide mg, mL and syringe units answers why 1.7 mg and other drug amounts have no universal syringe-unit conversion and reviews refill changes and FDA error reports.
Milligrams, milliliters, and syringe units are different
For preparation questions, our semaglutide mixing-chart guide explains why a total amount and a generic recipe cannot verify a product or replace the dispensing pharmacy’s instructions.
Milligrams measure an amount of medicine. Milliliters measure liquid volume. Syringe markings indicate a volume scale for that syringe; they do not establish a universal semaglutide dose.
Consequently, a question such as “How many units is 2.4 mg?” cannot be answered safely from the milligram number alone. The actual preparation’s concentration, the prescribed amount, and the syringe must all be known and confirmed by the dispensing team. Another person’s chart may refer to a different concentration.
FDA reports dosing errors involving compounded semaglutide, including cases requiring hospitalization. Ask the pharmacist to demonstrate the prescribed measurement using the supplied vial and syringe, and explain it back. This article intentionally does not provide a generic units-conversion table.
How many milligrams are 40 units of semaglutide?
There is no universal 40-unit-to-milligram answer. A unit marking on a syringe is not a semaglutide dose in milligrams. The exact preparation, concentration, prescribed volume and syringe scale must be identified together. Ask the dispensing pharmacist to show the correct marking for this prescription, especially after a refill or concentration change; do not borrow a chart from another vial or draw medicine out of a branded pen.
What if the compounded vial has a new concentration?
Treat that as a reason for fresh instructions. Do not reuse an old marking merely because the ingredient or prescription service is unchanged. Check the concentration, prescribed dose, total quantity, beyond-use date, storage, and whether additional ingredients are present.
Compounded drugs are not FDA-approved generic versions of Ozempic or Wegovy. FDA also warns that semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide used in approved products. A similar name is not evidence of equivalence.
For CoreAge Rx semaglutide information, request the exact preparation, dispensing pharmacy, and written administration plan. Branded trial results and pen instructions should not be transferred automatically to a different preparation.
Missed doses and restarting need product-specific advice
Ozempic injection, Wegovy injection, and daily tablets have different missed-dose instructions. A long interruption is also different from a single late dose. Do not apply one brand’s rule to another simply because both contain semaglutide.
The current Wegovy injection label directs restarting escalation at a lower dose after two or more consecutive missed doses to reduce gastrointestinal risk. The appropriate restart should be confirmed with the prescriber. Daily tablet labels tell patients to skip a missed dose and take the next one the following day, rather than doubling up.
Use our missed-dose and restart guide and the exact package instructions. If a dosing error may have occurred, contact the treating team or Poison Control promptly; severe symptoms require urgent care.
Safety questions belong beside every chart
Before treatment, review thyroid cancer/MEN2 history, serious allergy, severe stomach-emptying problems, relevant eye disease, pregnancy plans, and other medicines. Insulin or sulfonylureas can increase low-glucose concerns. Approved semaglutide labels include important precautions that a dose table cannot summarize completely.
Severe persistent abdominal pain, repeated vomiting, inability to keep fluids down, fainting, or serious allergic symptoms should not be treated as routine escalation. Our semaglutide side-effects guide explains when to seek help. Tell the procedural team before anesthesia or deep sedation as well.
The best dosage chart is the one that matches the actual prescription and is understood by the person using it. If the brand, route, indication, concentration, or device is uncertain, resolve that uncertainty with the prescriber or pharmacist before the next dose.
Educational information for adults; individual treatment decisions require a qualified clinician. Sources checked September 26, 2026. Original AI-generated article illustrations depict fictional people and objects, not patient outcomes. Other editorial images are illustrative. Graphics summarize the cited sources.
